PARP7 and nucleic acid-driven oncosuppression  

作　　者：Flavie Naulin Emma Guilbaud Lorenzo Galluzzi 

机构地区：[1]Department of Radiation Oncology,Weill Cornell Medicine,New York,NY,USA [2]Sandra and Edward Meyer Cancer Center,New York,NY,USA [3]Caryl and Israel Englander Institute for Precision Medicine,New York,NY,USA

出　　处：《Cellular & Molecular Immunology》2024年第11期1177-1179,共3页中国免疫学杂志(英文版)

基　　金：supported(as a PI,unless otherwise indicated)by one NIH R01 grant(#CA271915);by two Breakthrough Level 2 grants from the US DoD BCRP(#BC180476P1,#BC210945);by a grant from the STARR Cancer Consortium(#I16-0064);by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP(#W81XWH2120034,PI:Formenti);by a U54 grant from NIH/NCI(#CA274291,PIs:Deasy,Formenti,Weichselbaum);by the 2019 Laura Ziskin Prize in Translational Research(#ZP-6177,PI:Formenti)from the Stand Up to Cancer(SU2C)Foundation;by a Mantle Cell Lymphoma Research Initiative(MCL-RI,PI:Chen-Kiang)grant from the Leukemia and Lymphoma Society(LLS);by a Rapid Response Grant from the Functional Genomics Initiative(New York,US);by a pre-SPORE grant(PIs:Demaria,Formenti);a Collaborative Research Initiative Grant and a Clinical Trials Innovation Grant from the Sandra and Edward Meyer Cancer Center(New York,US);by startup funds from the Dept.of Radiation Oncology at Weill Cornell Medicine(New York,US);by industrial collaborations with Lytix Biopharma(Oslo,Norway),Promontory(New York,US)and Onxeo(Paris,France);by donations from Promontory(New York,US);the Luke Heller TECPR2 Foundation(Boston,US),Sotio a.s.(Prague,Czech Republic);Lytix Biopharma(Oslo,Norway);Onxeo(Paris,France);Ricerchiamo(Brescia,Italy);Noxopharm(Chatswood,Australia).

摘　　要：TCDD-inducible poly(ADP-ribose)polymerase(TIPARP,best known as PARP7)has previously been shown to promote oncogenesis by limiting the cytosolic accumulation of potentially interferogenic nucleic acids in malignant cells or the precursors thereof.Recent data indicate that the oncogenic activity of PARP7 is derived at least partially from its ability to suppress apoptotic cell death upon mono-ADP-ribosylation of FOS-like 1,AP-1 transcription factor subunit(FOSL1,best known as FRA1)[1].

关 键 词：INDUCIBLE PARP MONO 

分 类 号：R730.2[医药卫生—肿瘤]